Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy

Cancer

Volumn 117, Issue 17, 2011, Pages 3933-3942

  Feifer, Andrew H ^a   Elkin, Elena B ^a   Lowrance, William T ^a   Denton, Brian ^a   Jacks, Lindsay ^a   Yee, David S ^a   Coleman, Jonathan A ^a   Laudone, Vincent P ^a   Scardino, Peter T ^a   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

lymph nodes; lymphadenectomy; minimally invasive surgery; open, robotic, and laparoscopic radical prostatectomy; prostate cancer; Surveillance, Epidemiology, and End Results Medicare

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; GLEASON SCORE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE RADICAL PROSTATECTOMY; MINIMALLY INVASIVE SURGERY; OPEN RADICAL PROSTATECTOMY; PELVIS LYMPHADENECTOMY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SURGICAL TECHNIQUE;

AGED; AGED, 80 AND OVER; HUMANS; LAPAROSCOPY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; PELVIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SEER PROGRAM;

EID: 80051952516     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25981     Document Type: Article

References (47)

1. National Cancer Institute, National Institutes of Health. Prostate cancer home page. Accessed November 1, 2010.
2. Welch HG, Albertsen PC,. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009; 101: 1325-1329.
3. Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008; 53: 950-959. (Pubitemid 351434496)
4. Walsh PC,. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol. 2000; 163: 1802-1807. (Pubitemid 30366740)
5. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009; 302: 1557-1564.
6. Guillonneau B, Vallancien G,. Laparoscopic radical prostatectomy: the Montsouris experience. J Urol. 2000; 163: 418-422. (Pubitemid 30060483)
7. Mulhall JP, Rojaz-Cruz C, Muller A,. An analysis of sexual health information on radical prostatectomy websites. BJU Int. 2010; 105: 68-72.
8. Klein EA, Bianco FJ, Serio AM, et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol. 2008; 179: 2212-2216; discussion 2216-2217.
9. Vickers AJ, Bianco FJ, Gonen M, et al. Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol. 2008; 53: 960-966.
10. Briganti A, Capitanio U, Chun FK, et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol. 2008; 54: 794-802.
11. Lowrance WT, Elkin EB, Jacks LM, et al. Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. J Urol. 2010; 183: 1366-1372.
12. Lowrance WT, Elkin EB, Eastham JA,. Minimally invasive vs open radical prostatectomy. JAMA. 2010; 303: 619-620; author reply 620.
13. Briganti A, Blute ML, Eastham JH, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009; 55: 1251-1265.
14. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003; 170: 1798-1803. (Pubitemid 37254931)
15. Scardino P,. Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Canc Netw. 2005; 3 (suppl 1): S29-S33.
16. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177: 2106-2131. (Pubitemid 46726449)
17. Cooperberg MR, Kane CJ, Cowan JE, Carroll PR,. Adequacy of lymphadenectomy among men undergoing robot-assisted laparoscopic radical prostatectomy. BJU Int. 2010; 105: 88-92.
18. Prasad SM, Keating NL, Wang Q, et al. Variations in surgeon volume and use of pelvic lymph node dissection with open and minimally invasive radical prostatectomy. Urology. 2008; 72: 647-652; discussion 652-653.
19. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732-748.
20. Bach PB, Guadagnoli E, Schrag D, et al. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002; 40: IV-19-IV-25.
21. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40: IV-3-IV-18.
22. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001; 58: 843-848. (Pubitemid 34017254)
23. Mohler JL,. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer [editorial]. J Natl Compr Canc Netw. 2010; 8: 145.
24. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974. (Pubitemid 28445094)
25. Zorn KC, Orvieto MA, Gong EM, et al. Robotic radical prostatectomy learning curve of a fellowship-trained laparoscopic surgeon. J Endourol. 2007; 21: 441-447. (Pubitemid 46764217)
26. Vickers AJ, Bianco FJ, Serio AM, et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007; 99: 1171-1177. (Pubitemid 47233067)
27. Zorn KC, Katz MH, Bernstein A, et al. Pelvic lymphadenectomy during robot-assisted radical prostatectomy: assessing nodal yield, perioperative outcomes, and complications. Urology. 2009; 74: 296-302.
28. Yates J, Haleblian G, Stein B, et al. The impact of robotic surgery on pelvic lymph node dissection during radical prostatectomy for localized prostate cancer: the Brown University early robotic experience. Can J Urol. 2009; 16: 4842-4846.
29. Guillonneau B, Cappele O, Martinez JB, et al. Robotic assisted, laparoscopic pelvic lymph node dissection in humans. J Urol. 2001; 165: 1078-1081. (Pubitemid 32210203)
30. Atug F, Castle EP, Srivastav SK, et al. Prospective evaluation of concomitant lymphadenectomy in robot-assisted radical prostatectomy: preliminary analysis of outcomes. J Endourol. 2006; 20: 514-518. (Pubitemid 44182223)
31. Feicke A, Baumgartner M, Talimi S, et al. Robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate cancer: surgical technique and experience with the first 99 cases. Eur Urol. 2009; 55: 876-883.
32. Touijer K,. Editorial comment on: robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate cancer: surgical technique and experience with the first 99 cases [serial online]. Eur Urol. 2009; 55: 884.
33. Vanni AJ, Moinzadeh A,. Lymphadenectomy in minimally invasive urologic oncology. Curr Opin Urol. 2008; 18: 163-166. (Pubitemid 351317384)
34. Silberstein JL, Derweesh IH, Kane CJ,. Lymph node dissection during robot-assisted radical prostatectomy: where do we stand? Prostate Cancer Prostatic Dis. 2009; 12: 227-232.
35. Catalona WJ,. Pelvic lymphadenectomy is essential to staging accuracy in most patients with stages A-2 and B prostate cancer before radical prostatectomy. Semin Urol. 1983; 1: 212-216.
36. Yu JB, Makarov DV, Sharma R, et al. Validation of the Partin nomogram for prostate cancer in a national sample. J Urol. 2010; 183: 105-111.
37. Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002; 20: 3206-3212. (Pubitemid 34831516)
38. Graefen M, Karakiewicz PI, Cagiannos I, et al. A validation of 2 preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol. 2002; 7: 141-146.
39. Daneshmand S, Quek ML, Stein JP, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004; 172: 2252-2255. (Pubitemid 39507502)
40. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001; 28: 555-565. (Pubitemid 32916759)
41. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169: 517-523. (Pubitemid 36132976)
42. Masterson TA, Bianco FJ Jr, Vickers AJ, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol. 2006; 175: 1320-1324; discussion 1324-1325.
43. Carver BS, Bianco FJJ, Scardino PT, et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol. 2006; 176: 564-568. (Pubitemid 43927886)
44. Cheng L, Zincke H, Blute ML, et al. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001; 91: 66-73. (Pubitemid 32052615)
45. Klein EA, Kattan M, Stephenson A, et al. How many lymphadenectomies does it take to cure 1 patient? Eur Urol. 2008; 53: 13-15; discussion 18-20. (Pubitemid 350166738)
46. Intuitive Surgical, Inc. Da Vinci Surgical System. Sunnyvale, CA: Intuitive Surgical, Inc. Accessed November 1, 2010.
47. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.